Equities

SymBio Pharmaceuticals Ltd

SymBio Pharmaceuticals Ltd

Actions
  • Price (USD)1.21
  • Today's Change0.00 / 0.00%
  • Shares traded20.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Aug 21 2024 19:29 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of JPY
(except for per share items)
Fiscal data as of Dec 31 202320232022
ASSETS
Cash And Short Term Investments6,5176,283
Total Receivables, Net9132,085
Total Inventory232469
Prepaid expenses391463
Other current assets, total3013
Total current assets8,0839,313
Property, plant & equipment, net069
Goodwill, net----
Intangibles, net0222
Long term investments----
Note receivable - long term----
Other long term assets8885
Total assets8,17010,433
LIABILITIES
Accounts payable047
Accrued expenses----
Notes payable/short-term debt00
Current portion long-term debt/capital leases----
Other current liabilities, total9571,877
Total current liabilities9571,924
Total long term debt00
Total debt00
Deferred income tax----
Minority interest----
Other liabilities, total3.713.39
Total liabilities9601,927
SHAREHOLDERS EQUITY
Common stock17,95317,548
Additional paid-in capital17,92817,523
Retained earnings (accumulated deficit)(28575)(26478)
Treasury stock - common(89)(88)
Unrealized gain (loss)----
Other equity, total(5.99)0.24
Total equity7,2108,506
Total liabilities & shareholders' equity8,17010,433
Total common shares outstanding4240
Treasury shares - common primary issue0.090.09
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.